Lundbeck/Biotie Aim To Open Up Alcoholism Market By Trying To Reduce, Not Stop, Drinking

H. Lundbeck AS is planning to file for approval in Europe in the second half of 2011 for nalmefene – a drug touted as a novel and potentially revolutionary way of treating alcoholism – but currently is not planning to file in the U.S., presumably due to intellectual property issues.